<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467672</url>
  </required_header>
  <id_info>
    <org_study_id>6228</org_study_id>
    <nct_id>NCT03467672</nct_id>
  </id_info>
  <brief_title>Interest of Eosinopia in the Diagnosis of Infection in the Emergency Department</brief_title>
  <acronym>SEPSISEO</acronym>
  <official_title>Interest of Eosinopia in the Diagnosis of Infection in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have described the interest of eosinopenia as a marker of infection in
      internal medicine or in intensive care units. Eosinopenia is an inexpensive and easily
      accessible biological marker of sepsis. Retrospective work in the adult emergency departments
      of Strasbourg University Hospitals has shown the good specificity of this biological sign for
      the diagnosis of infection. Our work aims to confirm the results by a more meaningful study.

      Main objective: Evaluation of the interest of eosinopenia in the diagnosis of bacterial
      infection in ED.

      Methodology: inclusion of all patients with criteria for bacterial infection in ED, inclusion
      of an equivalent number of uninfected control patients.

      Duration : 12 months Multicentric prospective study 6 centers : Strasbourg, Hôpital Nord
      Franche comté, Sélestat, Wissembourg, Colmar, Mulhouse
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>eosinopenia as a sepsis marker</measure>
    <time_frame>102 month</time_frame>
    <description>Evaluation of the interest of eosinopenia in the diagnosis of infectious states in emergencies.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Eosinopenia</condition>
  <arm_group>
    <arm_group_label>Infected patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnosis of bacterial infection</intervention_name>
    <description>use of eosinopenia in the diagnosis of bacterial infection</description>
    <arm_group_label>Infected patients</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any adult emergency counseling subjects who benefit from the routine practice of NFS for
        any indication.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  major patient

          -  patient suspected of infection and benefiting from the routine practice of NFS,
             whatever the indication during his / her visit to the emergency room.

          -  patient with or without criteria for bacterial infection

          -  patient affiliated to a social security scheme

          -  patient (or legal representative) who has agreed to participate in the study

        Exclusion Criteria:

          -  anti tumor chemotherapy

          -  immunosuppressive treatment

          -  corticotherapy

          -  antibiotherapy in progress

          -  malignant hemopathy

          -  evolutionary cancer

          -  refusal to participate in the study

          -  subjects under safeguard of justice

          -  subject under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles-Eric Dr. LAVOIGNET</last_name>
    <phone>03 84 98 33 97</phone>
    <email>Charles-eric.lavoignet@hnfc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascal BILBAULT</last_name>
    <phone>03 88 12 86 82</phone>
    <email>Pascal.Bilbault@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH de COLMAR</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie PINCEMAILLE-CHAMPION</last_name>
      <phone>03 89 12 40 00</phone>
      <email>pincemaillesophie@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de MULHOUSE</name>
      <address>
        <city>Mulhouse</city>
        <zip>68051</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques SCHMITT</last_name>
      <phone>03 88 64 64 64</phone>
      <email>schmitt.jacques1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles-Eric LAVOIGNET</last_name>
      <phone>03 84 98 33 97</phone>
      <email>Charles-eric.lavoignet@hnfc.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pascal BILBAULT</last_name>
      <phone>03 88 12 86 82</phone>
      <email>Pascal.Bilbault@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierrick LEBORGNE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Selestat</name>
      <address>
        <city>Sélestat</city>
        <zip>67600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Nord Franche comte</name>
      <address>
        <city>Trévenans</city>
        <zip>90400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles-Eric LAVOIGNET</last_name>
      <phone>03 84 98 33 97</phone>
      <email>Charles-eric.lavoignet@hnfc.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hakim SLIMANI</last_name>
      <phone>03 84 98 34 11</phone>
      <email>hakim.slimani@hnfc.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ch Wissembourg</name>
      <address>
        <city>Wissembourg</city>
        <zip>67166</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fanny SCHWEITZER</last_name>
      <phone>03 88 54 11 11</phone>
      <email>fannyschweitzer@laposte.net</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

